CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

  • Current Quote
  • Stock Chart
$3.910.00 (0.00%)
Day High:$4.05
Day Low:$3.90
04/21/174:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345


Recent News

Mar 08, 2017CTI BioPharma to Present at the 29th Annual ROTH Conference
SEATTLE, March 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. PT/6:30 p.m. ET in Dana Point, CA. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutica... 
Printer Friendly Version
Mar 02, 2017CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
SEATTLE, March 2, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2016. "The presentation of detailed results from the Phase 3 PERSIST-2 trial of pacritinib at the ASH Annual Meeting in December demonstrated that pacritinib may have potential to address a critical unmet need for myelofibrosis patients with low blood platelets or those ineligible to receive, intolerant of or which have insu... 
Printer Friendly Version
Feb 27, 2017CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
SEATTLE, Feb. 27, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors effective March 20, 2017. Dr. Craig succeeds Richard Love, interim President and CEO who will continue to serve on the company's Board of Directors.  Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the US and Eu... 
Printer Friendly Version


Mar 14, 2017
CTI BioPharma Corp at the 29th Annual ROTH Conference
Mar 02, 2017
Q4 2016 CTI BioPharma Corp Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.